Home > Services > Fusion Platform for Therapeutic Proteins & Nanobodies
   Fusion Platform for Therapeutic Proteins & Nanobodies

 

ProtTech has developed a novel AT-fusion platform (patent pending) to increase the in vivo half life of cell signaling proteins and nanobodies for therapeutic applications.

Cell signaling proteins such as cytokines and growth factors often have a small molecular weights and a very short in vivo half life. The essential physiological functions of those signaling molecules make them an important class of medicines to treat various human diseases. However, the poor pharmacokinetics of those molecules largely limits their therapeutic application.

Several methods have been developed to increase the half life of the signaling proteins, for example, protein pegylation, Fc fusion and Albumin fusion. However, pegylation often lead to a dramatic decrease of its biological activity of a signaling protein, Fc-fusion protein requires mammalian cell expression, which often involves high development and production cost. The yield of production is often low due to the toxicity of the singaling proteins to the host cells. And the biological activity of the Fc fusion proteins may be compromised due to the dimer structure of the fusion protein that interferes with the binding to the receptor. Albumin fusion can be expressed in yeast cells. However, the yeast glycan modification (high mannose) pose a serious immunogenic risk, and degradation of the products is often very challenge for process development.

We have developed a large number of signaling protein fusions, and we have demonstrated that our fusion proteins can be expressed in E. coli cell in an active form at a high yield(>10g/L). The biological activity of the fusion proteins are comparable to the native molecules, and have low immunogenicity.

Similarly, Nanobody, or VHH antibody fragment has a similar MWt and half-life issue for therapeutic use. We have demonstrated that our AT-fusion platform is very effective to increase its in vivo half-life, while retains their valuable properties such as thermo stability, affinity, and capable expression in E. coli system.

Please Contact Us if you are interested in our AT-fusion protein platform for the signaling protein or nanobody of your interest. We’ll be able to complete the whole development project and deliver fusion protein to you for testing in 2-3 months.